BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Religare upgrades Sun Pharma to buy from hold
Religare in a note said that Sun Pharma reported a stellar Q2 with strong EBITDA margins and profit after tax. It sees multiple near-term triggers for the stock such as resolution of issues at Mohali and Halol plants, upside from gBenicar's authorised launch and above-expected Ranbaxy's synergies. It adds that post the recent correction, the stock appears to be favourably valued at the lower end of its historical band and Religare has upgraded Sun Pharma to buy from hold for target price of Rs 875.